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Abstract
Introduction. Rapid differentiation between Staphylococcus aureus (SA) and coagulase- negative staphylococci (CoNS) is criti-
cal in clinical infection. Direct matrix- assisted laser desorption/ionization time- of- flight (MALDI- TOF) identification from blood 
culture is highly accurate, but is associated with a significant failure rate, delaying identification. However, MALDI- TOF failure 
may itself be indicative of CoNS infection.
Aim. We sought to examine whether failure of MALDI- TOF direct ID was indicative of CoNS infection and could be used as a 
diagnostic tool to promote antimicrobial stewardship.
Methodology. Results of Gram stains, MALDI- TOF identification and formal identification were extracted from the large, multi- 
centre RAPIDO trial. All blood cultures with presumed staphylococci were included. MALDI- TOF performance (correct identifi-
cation, incorrect identification, failed identification) was calculated for each sample and across sites. Risk of SA disease was 
calculated for each group (correct, incorrect, failed) and across sites. Logistic regression was used to identify if clinical features 
are associated with MALDI- TOF performance.
Results. In the RAPIDO trial, 4312 patients were allocated to the MALDI- TOF arm. After exclusions, 880 patients were eligible 
and had a blood culture with a Gram stain consistent with presumed staphylococci. In total, 204 of these (23.2 %) were ulti-
mately identified as SA. MALDI- ID was successful 83.9 % of the time, and was 100 % accurate when successful. Failure was 
more common in CoNS isolates (124/641, 19.3 %) than in SA (13/191, 6.4 %). When MALDI- TOF failed, the risk of SA disease was 
9.2 % across the whole cohort, although failure rates and risk of SA disease varied significantly between centres. MALDI- TOF 
failure was independent of clinical characteristics.
Conclusion. Presumed staphylococci that fail direct MALDI- TOF identification from blood culture are significantly more likely 
to be CoNS isolates than SA. In low- risk or low- prevalence settings, SA therapy can be withheld if MALDI- TOF is unsuccessful.
INTRODUCTION
Matrix- assisted laser desorption/ionization time- of- flight 
(MALDI- TOF) identification has revolutionized the clinical 
microbiology laboratory, reducing the usage of complex 
biochemical testing, and increasing the rapidity of microbial 
diagnosis, with two large commercial systems available [1, 2]. 
The RAPIDO trial aimed to identify if there was any value 
in performing MALDI- TOF direct from blood culture, to 
facilitate early diagnosis and management of the identified 
organism. This was a randomized controlled trial (RCT) 
that compared traditional testing (Gram stain performed on 
positive blood culture, followed by growth then identifica-
tion by phenotypic testing or MALDI) versus MALDI- TOF 
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trial showed that direct MALDI did not appear to make an 
impact on clinical outcomes, although there was a trend for 
reduced mortality in the subgroup with Pseudomonas aerugi-
nosa, often not covered with empirical therapy [3].
Despite this, there is increasing use of MALDI- TOF direct 
from blood culture, and it is common in many clinical labo-
ratories [2]. Generally, it is reliable from blood culture, with 
around 80 % of organisms being identified correctly, with the 
vast majority of these having the ID subsequently confirmed 
by traditional testing or MALDI- TOF on the cultured isolate 
[2].
Clinicians who use MALDI- TOF are now faced with another 
problem: what to do when the isolate fails to identify directly 
from blood culture? This situation is most common with 
presumed staphylococci, where the management of Staphy-
lococcus aureus (SA) infection is often radically different from 
other staphylococci, whose prevalence is generally signifi-
cantly higher. In most cases of SA bloodstream infection, 
therapy is urgent and mandated for a long period (usually a 
minimum of 2 weeks of intravenous treatment), whereas with 
coagulase- negative staphylococci (CoNS), management is not 
required at all or is much less aggressive [4].
As clinical experience of the direct use of MALDI- TOF has 
increased, there has been an increasing incidence of this 
problem. In our laboratory, organisms unable to be directly 
identified often turned out to be CoNS, although this was 
purely based on observation.
In this post- hoc analysis of data from the RAPIDO trial, we 
aimed to see if this observation was true, and whether any 
useful prognostic information could be gained from isolates 
that failed to identify via direct MALDI- ID, and whether the 
absence of a direct MALDI- ID should alter management of 
presumed staphylococci identified on the Gram stain.
METHODS
Population
This study undertook post- hoc analyses of data from the 
RAPIDO trial, and a full protocol of the trial is available with 
the original publication [3]. Briefly, the RAPIDO trial was 
a multi- centre RCT that compared direct MALDI- ID from 
blood culture bottles to traditional management of a positive 
blood culture. This reduced the time to pathogen identifica-
tion by 24 h, but did not improve mortality. In the trial, both 
bottles of a standard blood culture set were used as normal, 
with MALDI identifications being performed usually only on 
the first one (as would be standard practice). All MALDI was 
performed using the Bruker Sepsistyper system.
In this analysis, we aimed to identify all patients with possible 
staphylococcal infection in the direct MALDI- ID arm, to 
assess the prognostic value of a failed MALDI identification.
Outcome measures
The primary outcome for this analysis was the prevalence of 
SA compared to any other Gram- positive cocci (GPC) using 
the final identification. The secondary outcome was MALDI-
 ID failure.
Statistical analysis
For our primary analysis, we identified all patients who were 
in the direct MALDI arm, and identified all those whose 
Gram stain would have been GPC in clusters (i.e. presumed 
staphylococci), such as Staphylococcus or Microcococcus. The 
RAPIDO trial did not record the Gram stain findings in 
more detail than GPC, so all organisms that would have not 
had a stain supporting a Staphylococcus identification were 
removed.
Next, we calculated the prevalence of SA as compared to 
any other GPC using the final identification. This was done 
for the population as a whole and also separately for each 
individual site, assuming there may be a different prevalence 
of SA at each site depending on their patient population. We 
then identified all bottles that had a failed MALDI- ID, and 
recorded their final identification. Using this, we were able 
to calculate a pre- test probability of SA disease, given the 
presumptive Gram stain, and the post- test probability, given a 
failed MALDI- ID. This was performed for each site, allowing 
us to calculate estimates at the site level.
For our secondary analysis, logistic regression was used to 
investigate whether the MALDI- ID was independent of other 
predictive factors such as age, white cell count, site, fever and 
blood pressure. Definitions of these are contained within the 
full RAPIDO trial protocol [3].
All analysis was performed in R 3.6.1, using the tidyverse 
package.
RESULTS
In the trial, 8628 of 14 298 positive blood cultures were rand-
omized, with 4312 allocated to the MALDI- TOF arm. After 
excluding samples that were ineligible, or from patients who 
declined consent, 2197 participants were eligible for inclusion 
in this analysis.
In total, 1283/2197 initial MALDI- IDs from the initial bottle 
had a Gram stain consistent with GPC, and 880 of these 
were Staphylococcus or Micrococcus species; a breakdown is 
presented in Table 1. CoNS were more common than SA (641 
vs 204 isolates).
MALDI- ID was 100 % accurate when performed, with no 
isolate incorrectly identified. However, failure to ID occurred 
in (142) 16 % of the participants. SA was identified correctly 
by MALDI 93.6 % of the time, whereas both CoNS and 
Micrococcus were less accurately identified (80.7 and 85.7 % 
respectively).
Pre- and post-test probabilities
CoNS isolates and Micrococcus species were much more 
likely to have an inconclusive direct MALDI- ID. As such, the 
presence of an inconclusive direct MALDI- ID increased the 
3
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probability of the isolate being CoNS or Micrococcus, based 
on Bayes’ rule.
In the study as a whole, 23.2 % of included GPCs were SA, but 
this value was only 9.2 % of those with a failed ID. In other 
words, the probability of any given isolate with a Gram stain 
showing GPC being SA was 23.2 % before the MALDI- ID 
was performed, and 9.2 % if the MALDI was performed and 
failed. In contrast, the probability of an isolate being a CoNS 
or Micrococcus was 76.8 % before the MALDI- ID and 90.8 % 
if the MALDI- ID failed.
Performance between centres
Across the seven sites in the MALDI- TOF trial, there was 
variation in the prevalence of SA disease, with the lowest 
prevalence at site 2 (18.9 %) and the highest at site 4 (28.6 %) 
but also variation in MALDI- TOF performance, with failure 
rates of 6.4 % at site 2 and 34.6 % at site 6 (Table 2).
At three sites, (2, 4 and 7), no single failed MALDI ID subse-
quently turned out to have SA, despite sites 4 and 7 having a 
high prevalence of SA.
Logistic regression
Table 3 gives the baseline clinical characteristics of those with 
and without a failed MALDI- ID.
The results of the logistic regression model (with failed 
MALDI- ID as the outcome variable) are reported in Table 4. 
This showed that no clinical features were significantly 
associated with the MALDI result. Unsurprisingly, given the 
result above, certain sites were significantly associated with 
the performance of MALDI- TOF.
DISCUSSION
This paper shows failed MALDI- ID on a blood culture with 
a Gram stain showing GPC is suggestive that SA is unlikely 
to explain the result. Only 13 out of 142 failed MALDI- IDs 
were subsequently identified as SA, with a baseline rate of SA 
Table 1. Breakdown of initial MALDI results, for the three relevant organisms
Final ID (number of cases) MALDI ID result for each organism
Correct (n, %) Incorrect (n, %) Unable to ID (n, %)
Staphylococcus aureus (204) 191 (93.6 %) 0 (0.0 %) 13 (6.4 %)
CoNS (641) 517 (80.7 %) 0 (0.0 %) 124 (19.3 %)
Micrococcus (35) 30 (85.7 %) 0 (0.0 %) 5 (14.3 %)
Overall (880) 738 (83.9 %) 0 (0.0 %) 142 (16.1 %)
Table 2. Differential prevalence of SA, and performance of MALDI, 
across the sites
Site (no. of 
GPC isolates)
No. of GPC 
that were SA 
(%, n)
Failure rate of 
MALDI- IDs (%, n)
Post- test 
probability of SA 
(failed MALDI ID)
1 (n=142) 20.4 % (29) 21.8 % (31) 12.9 % (4/31)
2 (n=170) 18.9 % (32) 6.4 % (11) 0 % (0/11)
3 (n=231) 23.4 % (54) 13.4 % (31) 9.7 % (3/31)
4 (n=49) 28.6 % (14) 14.2 % (7) 0 % (0/7)
5 (n=174) 27.0 % (47) 13.7 % (24) 16.7 % (4/24)
6 (n=49) 22.4 % (11) 34.6 % (17) 11.8 % (2/17)
7 (n=65) 26.2 % (17) 32.3 % (21) 0 % (0/21)
Table 3. Basic clinical demographics of patients with successful and 
failed MALDI- IDs





Age (years; median, interquartile 
range, IQR)
69 (53, 80) 69 (56, 81)
Gender (% male) 387 (52 %) 86 (61 %)
On immunosuppressive drugs at 
time 0 (%)
75 (11 %) 19 (15 %)
Missing 53 11
On chemotherapy (%) 69 (9.8 %) 7 (5.3 %)
Missing 36 9
On ventilation at day 0 (%) 77 (11 %) 18 (14 %)
Missing 49 10
On vasopressors at day 0 (%) 56 (8.2 %) 19 (15 %)
Missing 55 14
Neutrophil count (×106/µl at day 0; 
median, IQR)
8.4 (5.3, 12.3) 9.5 (6.7, 14.2)
Missing 43 14







Systolic blood pressure on day 0 
(mean, sd)
126 (109, 145) 124 (111, 141)
Missing 101 19
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disease being around one- quarter. In three centres from this 
study, no single failed ID subsequently turned out to be SA.
This suggests that a failed MALDI- ID is generally helpful, 
and adds significant prognostic information, reducing the 
probability of SA disease from 23.2 to 9.2 % across the whole 
study. Importantly, the value of this depends on two factors: 
local SA prevalence, which affects the base ‘risk’ of SA disease, 
and local performance of MALDI- ID.
It is also clear that clinical and real- life MALDI- ID perfor-
mance is dependent both upon the technical skills of the 
operators (with large differences between centres), but also 
upon other unknown factors, impacting significantly on 
interpretability. For example, site 7 had a high prevalence of 
SA disease (26.2 %), and very high rate of MALDI- ID failure 
(32.3 %), but none of these failed IDs were identified as SA. In 
contrast, site 6 had a slightly lower prevalence of SA disease, 
an even higher rate of MALDI- ID failure, and 11.8 % of these 
were subsequently identified as SA. The reasons for this 
discrepancy deserve exploring in further research, and explo-
rations of potential options. It may be that this simply reflects 
weakness of the database developed by Bruker, or something 
specific about CoNS isolates that make them hard to identify.
Strengths and weaknesses
The strength of this study lies in robust data collection (as a 
subgroup of an RCT) and large numbers, so confident conclu-
sions can be drawn. However, the performance of MALDI- ID 
in real life may well be different from the RCT setting, and 
clearly varies by site. Interpretation of this paper will require 
local knowledge of SA prevalence, and of MALDI- ID failure 
rates. We only evaluated the Bruker Sepsityper system, as this 
was used in the RAPIDO trial, and we cannot comment on 
other MALDI- ID systems.
Comparisons with other literature
Previous research has shown the value of MALDI- TOF in 
direct identification of blood cultures, showing a significant 
decrease in time to identification in RAPIDO [3], and with 
observational data supporting the accuracy and timeliness 
of direct MALDI- TOF [1, 5–9]. Recent work on SA has 
shown the potential for rapid identification of methicillin 
resistance using a directly targeted assay with cefoxitin 
added to the droplets and incubated before addition of 
matrix [10].
There have been two relevant RCTs performed, RAPIDO 
in the UK and MALDITOF in Vietnam. RAPIDO included 
mortality as an endpoint, and showed no difference in patient 
mortality despite an impressive reduction in time to appro-
priate identification from blood sampling (median time to 
microbial identification: 38.5 h in the MALDI arm, 50.3 h 
in the conventional arm) [3]. In MALDITOF, the primary 
outcome was appropriateness of antibiotic therapy at 24 h; 
there was no difference found between either arm (41.4 % 
MALDI arm vs 39.7 % control arm, adjusted odds ratio 1.17, 
P=0.40). In exploratory analyses, there was also no difference 
in mortality between the two arms (16 % MALDI arm vs 
14.2 % control arm, adjusted odds ratio 1.13, P=0.59) [7]. The 
results of these studies suggest that there is limited mortality 
benefit from the use of MALDI- TOF, although there are clear 
potential advantages in laboratory processing, efficiency and 
practicality.
However, as far as we are aware, no previous study has identi-
fied features suggesting SA disease from a failed MALDI- ID, 
or utilized the failure of MALDI- ID as a diagnostic test in 
of itself, with most noting that MALDI- ID is simply reliable 
when it is successful.
CONCLUSION
A failed MALDI- ID is still useful. Most isolates which failed 
MALDI- ID were not SA, with the vast majority being CoNS. 
Although the prevalence of SA disease in this study was 
23.2 %, only 9.2 % of isolates that failed a MALDI- ID were 
subsequently identified as SA. Clinicians should utilize this 
information in clinical decisions, and should consider holding 
treatment for SA in patients with low pre- test probability of 
disease, and a failed MALDI- ID.
Table 4. Multivariable regression with failed MALDI- ID as the outcome 
variable
Variable Odds ratio (95 % confidence 
interval)
p- value
Age 0.99 (0.97, 1.00) 0.225
Gender (male) 0.78 (0.51, 1.19) 0.260
Chemotherapy in last 
month
2.67 (0.95, 9.61) 0.087
Neutrophil count at day 0 
or closest
0.99 (0.95, 1.02) 0.411
On ventilation at day 0 1.16 (0.58, 2.42) 0.687
Systolic blood pressure at 
day 0 or closest
1.00 (0.99,1.01) 0.81




drugs at time 0
0.65 (0.34,1.29) 0.20
Centre (largest as 
reference)
3 Reference
1 0.61 (0.32, 1.12) 0.11
2 2.04 (0.96, 4.65) 0.07
4 0.84 (0.31, 2.70) 0.75
5 1.15 (0.57, 2.36) 0.69
6 0.302 (0.13, 0.69) 0.004
7 0.405 (0.19, 0.85) 0.001
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